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Executive Summary 
It is widely believed that firms pursuing product modification strategies require one set of 
control mechanisms and that firms pursuing new product strategies require a different set of 
control mechanisms (Dewar & Dutton, 1986; Ettlie, Bridges, & O'Keefe, 1984; Kaluzny, 
Veney, & Gentry, 1984). However, few studies have examined the role of innovation 
strategies and control mechanisms in the innovation creation process. Using data from 45 
pharmaceutical firms I investigated the effects of innovation strategies and formal control 
mechanisms on innovation outcomes. The findings suggest the following: 
• First, strategic intent does not have a direct effect on innovation outcomes as 
hypothesized. Theories that focus on intended strategies did not receive support in 
this study. These results are consistent with the recent anecdotal evidence in 
business publications that suggest that the desire to be innovative and the 
commitment of innovation-targeted resources does not help organizations realize 
innovation outcomes (O'Reilly, 1991; Vanston, 1988). 
• Second, it appears that control plays a more critical role than expected in the 
innovation creation process. Control mechanism effects were clear and systematic, 
although, not always supporting the hypotheses based on the literature. The results 
suggest that the innovation process is not stochastic and that managers can use 
formal control mechanisms to proactively guide the process. 
• Third, the determinants of product modifications and new products do not appear to 
be different. All three types of control mechanisms, input, process, and output, 
were found to be positively related to both the number of product mcxlifications and 
new products. 
• Fourth, although strategic intent did not have a direct effect on innovation 
outcomes, it does have an indirect effect on innovation outcomes through control 
mechanisms. Although not explicitly tested in this research, strategic intent had a 
direct effect on control mechanisms, which in turn affected innovation outcomes. 
The results clearly suggest that managers must choose control mechanisms that 
support innovation strategies. 
References: Dewar & Dutton, Management Science, (vol. 32), pp. 1422-1433; Ettlie, Bridges, & O'Keefe, 
Management Science (vol. 30), pp. 682-695; Kaluzny, Veney, & Gentry, Health and Society 
(vol. 52), pp. 51-82; O'Reilly, Fortune, June 3, pp. 48-63; Vanston, Business Week, June 13, 
pp. 8. 
Purpose of the Study 
Although innovation strategies (strategic goals) and realized innovation outcomes (product 
modifications and new products) represent different endpoints of the innovation process, 
little empirical work exists that has attempted to link innovation strategies and innovation 
outcomes. The overall purpose of this research was to study formal mechanisms that 
managers can use to influence the innovation process in their R&D laboratories to 
successfully realize innovation goals. More specific sub goals are listed as follows: 
• First, this project examines the determinants of the innovation creation process in 
R&D laboratories. Prior research examining the determinants of innovation 
has focused on innovation adoption (e.g., once the NOW checking account 
was created at one bank, NOW accounts were adopted by the rest of the banking 
industry), but not innovation creation. Researchers examining innovation creation 
have described innovations across a product's life cycle (e.g., automobiles, starting 
with the Ford Model T), but not the determinants of the technical innovations 
themselves (Abernathy & Clark, 1988; Tushman & Anderson, 1986). 
• Second, the project examines the match between innovation strategies and control 
mechanisms and their corresponding affects in achieving product modifications 
versus new products. It was hypothesized that different innovation strategies (the 
strategic intent to pursue product modifications versus the strategic intent to pursue 
new products) require differential control mechanisms. Specifically, it was 
expected one set of control mechanisms would enhance the pursuit of product 
modifications, and that the same set of control mechanisms would hamper the 
pursuit of new products. 
• Third, the project examines a more encompassing set of control mechanisms than 
previously studied. Although process control mechanisms (targeting behaviors and 
activities) have been the most studied type of control, they also have been the least 
recommended form of control when the transformation process is uncertain; for 
example in the research and development process. Therefore this project also 
looked at input controls (specialist diversity, specialist depth, and 
professionalization) and output controls (goal specificity, emphasis on outcomes in 
evaluation, and rewards and bonuses linked to results), in addition to process 
controls (centralization, documentation, formalization, frequency of performance 
appraisals). · 
References: Abernathy & Clark, In Tushman & Moore (Eds.), Readings in the Management of Innovation. 
pp. 55-78; Tushman & Anderson, Administrative Science Quarterly (vol. 31), pp. 439465. 
Definitions 
Strate~c Intent Variables 
• Strategic Intent to Pursue New Products/Drugs -The extent to which top management emphasizes new 
product development as a vital element of its strategy and as a means to compete. 
• Strategic Intent to Pursue Product Modifications -The extent to which top management emphasizes 
improvements to existing products as a vital element of its strategy and as a means to compete. 
• R&D Spending/Sales- average R&D spending as a percentage of sales for 1979-83. 
• Targeted Percent of Sales from New Products- Targeted percentage of sales from new products for 1979-83. 
Organizational Control Variables 
• Use of Input Control Mechanisms- The extent to which control mechanisms control for the degree and 
variety of core knowledge, skills, experiences, and attitudes displayed on the job for R&D professionals. 
•• Specialist Diversity - the number of different scientific specialties 
•• Special Depth - the degree to which personnel are concentrated in a few core specialities. 
•• Professionalization - the number of years of specialized schooling and the propensity to seek contact 
with professional colleagues outside the immediate work setting. 
• Use of Process Control Mechanisms- The extent to which control mechanisms are used to regulate and 
monitor activities and behaviors displayed by R&D professionals. 
•• Centralization - the degree of decision-making authority at lower levels of the organization hierarchy. 
•• Documentation - the amount of record-keeping of work behaviors required by R&D professionals. 
•• Formalization - the extent that rules governing behavior are precisely and explicitly formulated. 
•• Frequency of Performance Appraisals- the number of times behavior is measured and evaluated. 
• Use of Output Control Mechanisms- The extent to which control mechanisms are used to control results 
and outcomes produced by R&D professionals. 
•• Goal Specificity- the extent to which goals are explicitly, clearly defined, and provide 
unambiguous criteria for selecting among alternative outcomes. 
•• Rewards and Bonuses Linked to Results - the degree of public recognition R&D professionals 
receive for outstanding achievements. 
•• Emphasis on Outcomes - the degree to which the quantity of outcomes is emphasized in 




New Products- were drugs approved by the FDA representing chemical structures never previously available 
in the U.S. to treat a particular disease (New Chemical Entities). 
Product Modifications- were drugs involving new dosage forms, new indications, formula changes, name 
changes, and status changes. 
Research Method 
Sample and Sample Selection 
A comprehensive list of U.S. pharmaceutical firms was developed using multiple sources: 
the National Pharmaceutical Council's membership list, the Pharmaceutical Manufacturers 
Association's membership list, the Generic Association's membership list, Medical 
Advertisin~ News (Top 50 Pharmaceutical Firms Special Issue), Paul de Haen's New 
Product Survey and New Product Index, Pharmaceutical Manufacturers of the United 
~. R&D Laboratories in the U.S., Physician's Desk Reference, and Approved Dru~ 
Products with Therapeutic Equivalence Evaluations. After excluding firms that no longer 
existed, were duplicate listings, or had no in-house R&D, a final sample population of 154 
firms remained. Fifty-five agreed to participate and provided full or partial data, 
constituting a response rate of 35.71%. Forty-five complete sets of questionnaires were 
completed by both the CEO (or a Senior Level Manager) and R&D Director and used for 
this study. Fourteen of the firms in the sample were members of the National 
Pharmaceutical Council. 
Data Collection 
Two primary types of data collection methods were used for this study: archival data 
collection and questionnaire data collection methods. An archival data methodology was 
used to collect data for innovation outcomes. A questionnaire methodology was used to 
collect data for strategic intent and control mechanisms. 
Innovation data was collected from archival sources from 1984-1988. CEOs were asked 
retrospective questions concerning strategic intent to innovate during 1979-1983. R&D 
Directors were asked retrospective questions concerning control mechanisms in their firms' 
R&D laboratories during 1979-1983. 
Sample Characteristics 
Average Range 
Senior Level Manager Characteristics 
Years in Current Position 7.24 1.00 to 31.00 
Years in Firm 14.18 2.00 to 31.00 
Years in Industry 17.70 2.00 to 36.00 
R&D Director Characteristics 
Years in Current Position 6.47 1.00 to 36.00 
Years in Firm 13.58 1.00 to 37.00 
Years in Industry 18.29 1.00 to 37.00 
Business Unit Characteristics 
Number of Employees 2722.68 11.00 to 31,500 
ROI 14.90 -2.50 to 42.45 
ROA 9.90 -2.50 to 42.45 
Number of New Products (NCEs) .87 0.00 to 11.00 
Number of Product Modifications 3.56 0.00 to 14.00 
R&D Laboratory Characteristics 
Number of Employees in R&D Laboratory(ies) 370.87 1.00 to 3356.00 
R&D Spending/Sales 12.45 2.45 to 32.45 
Targeted Percent of Sales from New Products 22.45 2.45 to 52.45 
Primary Findings 
Influence of Strategic Intent on the Number of 
Product Modifications and New Products 
Do pharmaceutical firms with a higher level of commitment to product 
modifications exhibit a greater number of product modifications and new 
products? 
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Do pharmaceutical firms with a higher level of commitment to new products 
exhibit a greater number of product modifications and new products? 
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Influence of Strategic Intent on the Number of 
Product Modifications and New Products 
(continued) 
Do pharmaceutical firms that spend a higher level of R&D spending as a 
percentage of sales exhibit a greater number of product modifications and new 
products? 
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Do pharmaceutical firms that target a higher percentage of sales to be 
generated from new products exhibit a greater number of product 
modifications and new products? 
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Comments: 
Influence of Strategic Intent on the Number of 
Product Modifications and New Products 
(continued) 
In general, there were few differences between pharmaceutical firms with 
respect to achieving higher level of product modifications and new products 
for the strategic intent variables. The only exception was that firms that 
exhibited higher levels of commitment to new products exhibited a higher 
level of product modifications (note that this was the only statistically 
significant finding for the strategic intent variables). 
Influence of Input Control Mechanisms on the Number of 
Product Modifications and New Products 
Do pharmaceutical firms with higher levels of specialist diversity in their R&D 
laboratories exhibit a greater number of product modifications and new 
products? 
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Do pharmaceutical firms with higher levels of specialist depth in their R&D 
laboratories exhibit a greater number of product modifications and new 
products? 
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Influence of Input Control Mechanisms on the Number of 
Product Modifications and New Products 
(continued) 
Do pharmaceutical firms with higher levels of professionalization in their R&D 
laboratories exhibit a greater number of product modifications and new 
products? 





I I I I I I I I 
0.00 50.00 100.00 
Comments: 
Pharmaceutical firms with higher levels of specialist diversity and 
professionalization and lower levels of specialist depth exhibited higher 
levels of product modifications and new products (note that effects of specialist 
diversity, specialist depth, and professionalization on product 
modifications and new products were statistically significant). 
Influence of Process Control Mechanisms on the Number of 
Product Modifications and New Products 
Do pharmaceutical firms with higher levels of centralization in their R&D 
laboratories exhibit a greater number of product modifications and new 
products? 
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Do pharmaceutical firms with higher levels of documentation in their R&D 
laboratories exhibit a greater number of product modifications and new 
products? 
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Influence of Process Control Mechanisms on the Number of 
Product Modifications and New Products 
(continued) 
Do pharmaceutical firms with higher levels of formalization in their R&D 
laboratories exhibit a greater number of product modifications and new 
products? 
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Do pharmaceutical firms with higher levels of frequency of performance 
appraisals in their R&D laboratories exhibit a greater number of product 
modifications and new products? 
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Influence of Process Control Mechanisms on the Number of 
Product Modifications and New Products 
(continued) 
Comments: 
Pharmaceutical firms with higher levels of centralization, documentation, 
formalization, and frequency of performance appraisals exhibited higher 
levels of product modifications and new products (note that effects of 
documentation and frequency of performance appraisals on product 
modifications and new products were statistically significant, while 
centralization and formalization were not). 
Influence of Output Control Mechanisms on the Number of 
Product Modifications and New Products 
Do pharmaceutical firms with higher levels of goal specificity in their R&D 
laboratories exhibit a greater number of product modifications and new 
products? 
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Do pharmaceutical firms with a greater emphasis on outcomes in their R&D 
laboratories exhibit a greater number of product modifications and new 
products? 
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Influence of Output Control Mechanisms on the Number of 
Product Modifications and New Products 
(continued) 
Do pharmaceutical firms with higher levels of rewards and bonuses linked to 
results in their R&D laboratories exhibit a greater number of product 
modifications and new products? 
I Average Level of Rewards and Bonuses Linked to Results I 
Product Modifications =::::::=:-
New Products ==:=:::t:-• 
I I I I I I I I 1- I I I 




Pharmaceutical firms with higher levels of goal specificity, emphasis on 
outcomes, and rewards and bonuses linked to results exhibited higher 
levels of product modifications and new products (note that effects of 
emphasis on outcomes and rewards and bonuses linked to results on product 
modifications and new products were statistically significant, while goal 
specificity was not). 
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